InterCure

company

About

InterCure is a medical device company focused on respiratory treatment that has developed and patented a technology platform.

  • Ra'anana,HaMerkaz,Israel
  • 51 - 100

Details

Last Funding Type
Post-IPO Equity
Last Funding Money Raised
$17.50M
Industries
Biotechnology,Health Care,Manufacturing,Medical Device,Therapeutics
Founded date
Jan 1, 1994
Number Of Employee
51 - 100
Operating Status
Active
Stock Symbol
tlv:INCR
Legal Name
InterCure Ltd

InterCure is a medical device company that has developed and patented a technology platform for respiratory-based treatment of cardiovascular and pulmonary diseases.

The Company has incorporated its "Interactive Respiratory-Pacing" technology platform into several product lines, the first two of which offer a new therapeutic class of non-drug treatments for two of the most widespread and costly disease states in the healthcare industry: hypertension and heart failure.

InterCure’s first market-ready product, RESPeRATE, is the only FDA-cleared, medical device clinically proven to lower high blood pressure with no side effects.

InterCure's heart failure product, InTone™ has successfully completed phase 2a efficacy clinical trials and is expected to be launched when it completes the regulatory approval process.

With its outstanding management team, the board of directors and a world-class Scientific Advisory Board, Intercure is poised to become the market leader in patient-focused medical devices that provide non-drug, no-side-effect treatment for some of the world's most prevalent and costly chronic conditions.

InterCure was founded in 1994 and is headquartered in Ra'anana, Israel.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
7
$41.90M
InterCure has raised a total of $41.90M in funding over 2 rounds. Their latest funding was raised on Feb 11, 2021 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Feb 11, 2021 Post-IPO Equity $8M 1 ARK Investment Management Detail
Nov 1, 2018 Post-IPO Equity $17.50M 2 GMF Capital Detail
Oct 27, 2011 IPO Detail
Apr 13, 2005 Series C $3M 2 Detail
Oct 30, 2001 Series B $4.50M 6 Medica Venture Partners Detail

Investments

Number of Investments
Number of Lead Investments
1
1
InterCure has made 1 investments. Their most recent investment was on Dec 23, 2015, when Fore Biotherapeutics raised $10M.
Date Company Name
Round Money Raised Industry Lead Investor
Series Unknown $10M Biotechnology Yes

Acquisition

InterCure has acquired 1 organizations. Their most recent acquisition was Canndoc on Sep 4, 2018. They acquired Canndoc for 0.

Date Company Name
Industry Acquisition Type Price
Sep 4, 2018 Canndoc
Alternative Medicine acquisition Detail